We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.27 | -15.9763313609 | 1.69 | 1.7216 | 1.41 | 461063 | 1.50710163 | CS |
4 | -0.69 | -32.7014218009 | 2.11 | 2.11 | 1.41 | 365044 | 1.73666199 | CS |
12 | -0.46 | -24.4680851064 | 1.88 | 2.355 | 1.41 | 429897 | 1.93259067 | CS |
26 | -0.58 | -29 | 2 | 3.62 | 1.36 | 654679 | 2.12633678 | CS |
52 | -1.78 | -55.625 | 3.2 | 3.62 | 1.3 | 451845 | 2.20118914 | CS |
156 | -26.88 | -94.9823321555 | 28.3 | 46.4 | 1.3 | 646882 | 18.2374119 | CS |
260 | -35.88 | -96.1930294906 | 37.3 | 53.762 | 1.3 | 611231 | 22.2611498 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions